Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NRX-101 for Treatment-Resistant Depression in Patients Receiving Transcranial Magnetic Stimulation Who Do Not Qualify for NRX101-011 (MIND1): Expanded Access Program

NCT05779267 is registered in ClinicalTrials.gov with NeuroRx, Inc. as lead sponsor.

NCT NCT05779267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NRX-101 for Treatment-Resistant Depression in Patients Receiving Transcranial Magnetic Stimulation Who Do Not Qualify for NRX101-011 (MIND1): Expanded Access Program
Lead sponsor
NeuroRx, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment-resistant depression